

Report

Subserosal Myoma Associated with Stump (Smooth Muscle Tumors of Uncertain Malignancy Potential): A Case Report

Meryem Lamrani^{1,*} , Khaoula Lakhdar¹, Oumaima Sardaoui¹, Yacir Alami², Fouad Tijami², Hafid Hachi², Zaki El Hanchi¹, Aziz Baydada¹

¹Department of Gynecology-Obstetrics and Endoscopy, University Hospital Center Ibn Sina of Rabat, Mohammed 5 of Rabat University, Rabat, Morocco

²Gynaecological-Mammary Unit of the National Institute of Oncology, Sheikh Fatma Hospital, Rabat, Morocco

Abstract

Smooth muscle tumors of the uterus are typically benign, but a rare subset known as smooth muscle tumors of uncertain malignant potential (STUMP) poses diagnostic challenges. First classified by the World Health Organization in 2003 due to their atypical histological features, STUMPs are difficult to distinguish from benign leiomyomas and malignant leiomyosarcomas. This case study describes a 53-year-old woman with a large abdomino-pelvic mass, initially suspected to be sarcoma. Clinical and imaging evaluations, including MRI, led to exploratory laparotomy, revealing a subserosal myoma associated with STUMP. Histopathological analysis confirmed the diagnosis, underscoring the complexities in differentiating STUMPs from other uterine tumors. STUMPs account for a portion of uterine sarcomas, and accurate diagnosis relies on specific histological criteria, including nuclear atypia, mitosis index, and tumor necrosis. Advanced imaging, such as dynamic MRI, helps improve differentiation between STUMP, leiomyosarcoma, and leiomyoma. Although STUMPs are rare, they typically have a better prognosis than leiomyosarcomas, with lower recurrence rates. However, due to their uncertain behavior, patients require long-term monitoring. The limited understanding of STUMPs highlights the need for continued research and clinical vigilance to improve diagnosis and management strategies.

Keywords

STUMP, Leiomyomas, Leiomyosarcomas

1. Introduction

Smooth muscle tumors of the uterus are common and mostly benign. Some tumors may present unusual anatomical-pathological aspects, leading to problems of differential diagnosis, notably with leiomyosarcoma. In 2003, the World Health Organisation classified these tumours as smooth

muscle tumours of uncertain malignant potential (STUMP) [1].

These are complex tumors, whose histological characteristics do not allow them to be classified as either benign or malignant [2]. Only clinical follow-up will reveal the true

*Corresponding author: meryemlamrani97@gmail.com (Meryem Lamrani)

Received: 4 November 2024; Accepted: 15 November 2024; Published: 29 November 2024



Copyright: © The Author (s), 2024. Published by Science Publishing Group. This is an **Open Access** article, distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

nature (benign or malignant) of the tumor. Numerous studies have sought to identify diagnostic markers for these tumors, based on histological and immunohistochemical criteria, but to date, none of these studies have defined the category of STUMP [3]. The absence of consistent diagnostic criteria and the uncertainties surrounding the diagnosis of STUMP have led to its overdiagnosis over the years [4]. In fact, according to Ip et al., a diagnosis of STUMP is appropriate when a tumor presents any unusual combination of the three previously mentioned features but does not meet the Stanford criteria for leiomyosarcoma. [5, 6]

This complexity in diagnosis underscores the importance of detailed case reports to enhance clinical understanding, as demonstrated in the following case study.

2. Case Presentation

We present the case of a 53-year-old female patient, without any particular personal history or family history of cancer, single, nulliparous nulligest. She was referred by her primary care physician to the National Institute of Oncology in Rabat, Morocco, for an abdomino-pelvic mass. The patient initially presented with altered general condition associated with constipation and pollakiuria.

Our clinical examination on admission revealed a patient in good general condition: conjunctiva was normally colored, blood pressure and heart rate were normal, BMI = 30, WHO = 0, ASA = 1.

Palpation of the abdomen revealed a large (25 cm long axis), hard, difficult to mobilize abdomino-pelvic mass.

Gynecological examination revealed a healthy cervix, and abdominal palpation combined with vaginal palpation revealed a mobile mass adjacent to the uterus. Rectal palpation revealed no infiltration or mass. The rest of the examination was normal.

Pelvic MRI revealed:

- An abdomino-pelvic mass of uterine origin measuring 19 x 17.5 x 25 cm, initially suggestive of sarcoma.

- A 76x62x175 mm left abdomino-pelvic formation, shaping the vascular structures, extending retroperitoneally and shaping the left ovarian vein. No pelvic adenopathy and small pelvic effusion.

- A 9 cm cystic lymphangioma of the left ovarian vein reaching the left renal vein.

As part of the investigations, a thoracoabdominal CT scan was performed which showed the absence of distant metastases but the presence of peritoneal nodules associated with sarcomatosis.

After multidisciplinary consultation, the patient underwent exploratory laparotomy in March 2022 and was found to have a uterine mass adherent to the small intestine, mild ascites, and nodules of peritoneal carcinosis: Total colpohysterectomy with bilateral adnexectomy, with resection of 80 cm of the last loop of bowel adherent to the mass, and with terminal-terminal bowel-gastric anastomosis. Partial resection of

the left cystic lymphangioma was also performed. Anatomic pathology revealed: A Total weight of 6525g. Very large subserosal myoma measuring 30 x 22 x 17cm associated with a smooth muscle tumor of uncertain malignant potential (STUMP).

Non-tumoral ileal resection, Lymph node biopsy: 01N-/01N,

Cytology: inflammatory ascitic fluid, Non-specific acute ulcerated appendicitis. No histological signs of malignancy.




Figure 1. Surgical specimen: 1-Polymyomatous uterus, 2- Grecic loop, 3-Cystic lymphangioma.



Figure 2. Surgical specimen: better visualization of cystic lymphangioma.






Figure 3. Two peroperative images of abdomino-pelvic mass resection with adhesiolysis.




Figure 4. Scan image of a smooth muscle tumor of uncertain malignant potential of the uterus.

Because of moderate signal intensity on T2-weighted scans, mass was thought to be smooth muscle tumor of uncertain malignant potential [10].

3. Discussion

There are numerous uterine smooth muscle tumours with well-defined clinical outcomes and histological criteria; These tumors are challenging to classify due to their overlapping features with both benign leiomyomas (LM) and malignant leiomyosarcomas (LMS), making definitive diagnosis difficult. Between these two extremes lie several variants with unusual histological features, clinical course and prognosis.

These are smooth muscle tumors of uncertain malignant potential [1]. STUMPs are very rare tumours, accounting for 1/3 of uterine sarcomas and 1.3% of uterine cancers [2].

Diagnosis of smooth muscle tumors is challenging due to a lack of specific features [1], and it is clinically indistinguishable from leiomyoma (LM) with no imaging techniques to differentiate them [2]. However, contrast-enhanced dynamic MRI can distinguish between LMS, STUMP, and LM

with 94% accuracy and 96% specificity [7]. Proton emission tomography with 18F Fluorodeoxyglucose (18F-FDG) has also shown high uptake in this tumor [8]. A thoraco-abdomino-pelvic CT scan should be requested to check for metastases, particularly pulmonary metastases from STUMP [1].

Histologically, three criteria are used to classify smooth muscle tumors as benign or malignant: nuclear atypia, mitosis index, and presence of tumor necrosis. Two of these criteria are required for a malignancy diagnosis. STUMP occurs when one malignancy criterion is present, but the second is difficult to assess [1]. Currently, no antibody can definitively identify the malignant nature of a smooth muscle tumor, although P53 and P16 have shown promise in uterine LMS, STUMP, and LM [9].

The CGH array technique can detect small chromosomal abnormalities not visible on standard karyotyping, aiding STUMP classification. If a STUMP has a flat chromosomal profile, it may suggest a leiomyoma, while abnormalities commonly seen in leiomyosarcomas suggest closer monitoring. However, the tumor's morphology remains the key factor in diagnosis, not its genomic profile [9].

Thus, the therapeutic approach differs from one school to another, ranging from simple myomectomy to total hysterectomy or even bilateral adnexectomy [1]. The preferred treatment for recurrence is surgical excision, followed by adjuvant therapies such as pelvic irradiation, chemotherapy (including doxorubicin and cisplatin), medroxyprogesterone, and gonadotropin-releasing hormone analogues [11-14].

The prognosis for STUMP is better than for LMS. Various studies have shown a significantly lower recurrence rate than LMS, and 5-year survival rates ranging from 92% to 100%. Given the uncertain nature and evolution of these tumors, patients should receive close, long-term clinical and radiological follow-up [1].

As noted by Ip et al., STUMPs are associated with the potential for delayed recurrences. However, they exhibit a higher median survival rate following recurrence compared to more aggressive malignant uterine neoplasms [15-17].

4. Conclusion

In conclusion, STUMPs are a rare and still poorly understood group of smooth muscle tumors. They are difficult to diagnose, as their clinical and radiological features are the same as those of leiomyomas, so only anatomopathology enables the diagnosis to be made. The prognosis is still uncertain, but studies suggest that it is better than for leiomyosarcomas.

Abbreviations

STUMP	Smooth Muscle Tumors of Uncertain Malignant Potential
MRI	Magnetic Resonance Imaging
BMI	Body Mass Index
WHO	World Health Organization
ASA	American Society of Anesthesiologists
LM	Leiomyomas
LMS	Leiomyosarcomas

Author Contributions

Meryem Lamrani: Conceptualization, Investigation, Resources, Writing – original draft, Writing – review & editing

Khaoula Lakhdar: Supervision

Oumaima Sardaoui: Validation

Yacir Alami: Methodology, Supervision, Validation

Fouad Tijami: Supervision, Validation

Conflicts of Interest

The authors declare no conflicts of interest.

References

- [1] Fibrome utérin associé à un STUMP à propos d'un cas, Authors: Mohammed Karam Saoud, Imane Benchiba, Nisrine Mamouni, Sanaa Errarhay, Chahrazad Bouchikhi, et Abdelaziz Banani Review: Pan Afr Med J. 2018 Oct 30; 31: 151 <https://doi.org/10.11604/pamj.2018.31.151.14135>
- [2] TUMEUR MUSCULAIRE LISSE UTERINE A POTENTIEL DE MALIGNITE INCERTAINE A PROPOS DE 3 CAS. Authors: Madi Tigani Guirema; Tshibola Mwamba Myriam.; Fdili Alaoui Fatima Zahra; Chaara Hikmat; Melhouf Moulay Ab Review: Revue Africaine et Malgache pour la Recherche Scientifique / Sciences de la Santé Vol.1, N° 1, Décembre 2018ISSN 2424-7243.
- [3] Les tumeurs musculaires lisses utérines à potentiel de malignité incertain (STUMP) étude multicentrique sur une série de 31 cas Authors: S. Crocea, G. MacGrogana, P. Lagarde b, A. Ribeiroa, E. Stoecklec, F. Guyonc, A. Floquet d, J.-C. Noë e, G. Perrot a, J.-M. Coindre, F. Chibon <https://doi.org/10.1016/j.annpat.2012.09.112> November 2012 Annales de Pathologie 32(5): S117.
- [4] Authors: Ip PP, Cheung AN, Clement PB. Review: Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009; 33: 992–1005. <https://doi.org/10.1097/PAS.0b013e3181a02d1c>
- [5] Authors: Ip PP, Tse KY, Tam KF. Review: Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol. 2010; 17: 91–112. <https://doi.org/10.1097/PAP.0b013e3181cfb901>
- [6] Authors: Dall'Asta A, Gizzo S, Musarò A, Quaranta M, Noventa M, Migliavacca C, Sozzi G, Monica M, Mautone D, Berretta R. Review: Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol. 2014 Oct 15; 7(11): 8136-42. PMID: 25550862; PMCID: PMC4270570.
- [7] Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma / smooth muscle tumor with uncertain malignant potential and benign leiomyoma. Authors: Lin G, Yang LY, Huang YT., Ng KK., Ng SH, Ueng SH, Chao A, Yen TC, Chang TC, Lai CH PMID: 26383110 <https://doi.org/10.1002/jmri.24998>
- [8] High 18F-FDG uptake for uterine smooth muscle tumor of uncertain malignant potential. 2015; Authors: Zhang R, Tian X, Qin L, Lu D, Shen J PMID: 25674868 <https://doi.org/10.1097/RLU.0000000000000727>
- [9] LES TUMEURS MUSCULAIRES LISSES DE L'UTERUS: DU BENIN AU MALIN Author: M. DEVOUASSOUX-SHISHEBORAN Affiliation: Institut de Pathologie multisite des Hôpitaux de Lyon, Site Sud-Antenne Nord -163 Chemin du grand Revoyet - Pierre Bénite Cedex Review: Livre des Résumés - Carrefour Pathologie 2017.
- [10] Review of Leiomyoma Variants Authors: Elizabeth Kagan Arleo, Peter E. Schwartz, Pei Hui, and Shirley McCarthy Author Info & Affiliations Volume 205, Issue 4 <https://doi.org/10.2214/AJR.14.13946>
- [11] Author: Clement PB. The pathology of uterine smooth muscle tumors and mixed endometrial stromal-smooth muscle tumors: a selective review with emphasis on recent advances. Review: Int J Gynecol Pathol. 2000; 19: 39–55. <https://doi.org/10.1097/00004347-200001000-00006>
- [12] Author: Mittal K, Popiolek D, Demopoulos RI. Review: Uterine myxoid leiomyosarcoma within a leiomyoma. Hum Pathol. 2000; 31: 398–400. [https://doi.org/10.1016/s0046-8177\(00\)80258-0](https://doi.org/10.1016/s0046-8177(00)80258-0)
- [13] Author: Clement PB, Young RH. Review: Atlas of gynecologic surgical pathology. 2nd edition. Philadelphia: WB Saunders; 2007. Article: Mesenchymal and mixed epithelial-mesenchymal tumors of the uterine corpus and cervix; pp. 194–235.
- [14] Authors: Berretta R, Patrelli TS, Faioli R, Mautone D, Gizzo S, Mezzogiorno A, Giordano G, Modena AB. Article: Dedifferentiated endometrial cancer: an atypical case diagnosed from cerebellar and adrenal metastasis: case presentation and review of literature. Review: Int J Clin Exp Pathol. 2013; 6: 1652–7.
- [15] Authors: Gizzo S, Ancona E, Patrelli TS, Saccardi C, Anis O, Donato D, Nardelli GB. Article: Fertility preservation in young women with cervical cancer: an oncologic dilemma or a new conception of fertility sparing surgery? Review: Cancer Invest. 2013; 31: 189. <https://doi.org/10.3109/07357907.2013.767343>

[16] Authors: Patrelli TS, Gizzo S, Di Gangi S, Guidi G, Rondinelli M, Nardelli GB. Article: Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature. Review: BMC Cancer. 2011; 11: 236. <https://doi.org/10.1186/1471-2407-11-236>

[17] Authors: Patrelli TS, Silini EM, Gizzo S, Berretta R, Franchi L, Thai E, Lukanovic A, Nardelli GB, Modena AB. Article: Extragenital Müllerian adenosarcoma with pouch of Douglas location. Review: BMC Cancer. 2011; 11: 171. <https://doi.org/10.1186/1471-2407-11-171>